NovaBay Trading Resumes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
NovaBay trading resumes
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBY
About NBY
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
- Earnings Performance: Netflix's Q4 earnings report revealed revenue of $12.16 billion, exceeding expectations, yet its Q1 guidance of $12.16 billion fell short of the $12.19 billion consensus, causing shares to drop 5.7% to $82.32 in pre-market trading.
- Earnings Per Share Outlook: The company anticipates Q1 earnings per share of 76 cents, below the consensus estimate of 81 cents, indicating pressure on user growth and profitability, which may undermine investor confidence.
- Other Stock Movements: Erasca Inc announced a proposed $150 million public offering, leading to a 6.2% decline in its pre-market share price to $9.20, highlighting market sensitivity to new stock issuances.
- Market Reaction: Kraft Heinz Co shares fell 5.3% to $22.51 as Berkshire Hathaway filed to sell up to 325 million shares, intensifying market concerns regarding its future performance.
Continue Reading
D.R. Horton Reports Q1 Net Income of $594.8M Exceeding Estimates
- Earnings Highlight: D.R. Horton reported a net income of $594.8 million for Q1 2026, translating to $2.03 per diluted share, surpassing the analyst estimate of $1.95, despite a revenue decline to $6.887 billion, showcasing the company's resilience amid market fluctuations.
- Sales Performance: While total revenue decreased from $7.613 billion year-over-year, sales exceeded expectations at $6.603 billion, indicating the company's strong sales capability in a competitive real estate market.
- Market Reaction: Amidst a broader market downturn, D.R. Horton's stock price remained relatively stable, reflecting investor confidence in its financial health, which may lay the groundwork for future growth.
- Industry Trends: Given the volatility in the real estate market, D.R. Horton's robust earnings report could attract more investor attention, particularly as economic uncertainties rise, positioning the company as a potential bellwether in the industry.
Continue Reading